Comment on Second eczema treatment pulled from PBS listing by Kathryn Nankivell

['Nicholas O Donoghue', 'Guest Author', '.Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow', 'Class', 'Wp-Block-Co-Authors-Plus', 'Display Inline', '.Wp-Block-Co-Authors-Plus-Avatar', 'Where Img', 'Height Auto Max-Width', 'Vertical-Align Bottom .Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow .Wp-Block-Co-Authors-Plus-Avatar'] Comments for AJP 2025-09-29 05:55:02

Manufacturer calls for reform of Health Technology Assessment after dropping application to list an eczema treatment on the PBS Pfizer withdraws application to list Cibinqo (abrocitinib) on the Pharmaceutical Benefits Scheme (PBS) over what it believes are unsustainable pricing and risk sharing arrangements. The decision comes after the Pharmaceutical Benefits Advisory Committee (PBAC) recommendedThis content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.